Eric Hong

Eric Hong is associated with SK Capital Partners, a New York–based private investment firm (430 Park Avenue, 18th Floor) focused on the specialty materials, specialty ingredients, and life sciences sectors. Source records list his role at the firm as an Associate on the investment side, a typical deal-team position responsible for transaction execution, financial modeling, and portfolio support rather than independently writing checks.

According to professional-data records, Hong earned a Bachelor of Business Administration (concentrations in Finance and Management) from Emory University (2011–2015). He began his career in investment banking at SunTrust Robinson Humphrey (STRH) before moving into private equity at SK Capital Partners.

The same records indicate that Hong has since transitioned out of finance and is identified as a First Lieutenant Officer in the U.S. Army Reserve, based in New York. He does not currently appear on SK Capital's published team roster, which is consistent with that career move. Because individual-level public detail on him is limited, much of what follows is firm-level context that frames the environment in which he worked as an Associate.

As an Associate, Eric Hong worked within — rather than set — SK Capital's investment strategy. The firm's stated approach:

• Sectors: Disciplined, specialist focus on material sciences, specialty ingredients (including food, feed, and pharma ingredients), and life sciences — areas where the team has operating as well as investing backgrounds.
• Deal types: Control buyouts, recapitalizations, and growth equity investments; frequently carve-outs of non-core divisions from large corporates (e.g., Chemtura's antioxidants business).
• Market segment: Operates two strategies — Flagship (upper-mid-market/large companies) and Catalyst (smaller, mid-sized companies).
• Scale: More than $9–10 billion in capital raised/AUM since its 2007 founding; its sixth flagship fund (Fund VI) closed at roughly $2.95 billion.
• What makes them say yes: Businesses in their target chemistries/ingredients/life-sciences niches where operational improvement, consolidation (buy-and-build), and sector expertise can transform performance.